fatty acid · for eye strain
Omega-3
Meant to improve the oily layer of your tears so your eyes dry out more slowly.
Say that in clinical terms
Omega-3 fatty acids improve meibomian gland function and tear film lipid layer quality, reducing evaporative dry eye that exacerbates eye strain. DHA also supports retinal photoreceptor membrane fluidity for efficient visual processing.
How strong is the research?
A 12-month trial in 535 adults with dry eye found fish oil did no better than placebo.
2 papers read, 1 against.
Who was studied: Patients with diagnosed dry eye disease, not healthy people tired from screens.
Extensive searching across PubMed, Cochrane, and general literature found no human RCT testing EPA or DHA supplementation for eye strain (asthenopia) as the primary or explicit secondary outcome. Every trial located targets dry eye disease (inadequate or poor-quality tear film) — a distinct condition from asthenopia (discomfort from sustained accommodation and convergence effort from screen use, reading, or driving). A 2015 RCT in computer vision syndrome patients (PMID 25697893) enrolled screen users but measured only dry eye endpoints (Schirmer, TBUT, Nelson grade), not eye strain or asthenopia. A 2023 narrative review on PUFAs and visual fatigue (PMID 37299596) exists but is a review arti
How much to take
daily with meals
1000–2000 mg
Omega-3s support tear film quality which reduces eye strain symptoms. DHA is particularly important for retinal health.
Before you take it
- FDA GRAS limit for dietary supplements: up to 5 g/day of combined EPA+DHA (not 3 g/day; the lower figure reflects an older FDA enforcement discretion letter, not the current GRAS determination).
- No formal Tolerable Upper Intake Level (UL) has been established by the IOM/NAM for EPA or DHA.
- Doses of 2–15 g/day may increase bleeding time by reducing platelet aggregation; clinically relevant when combined with anticoagulants (warfarin), antiplatelet agents (aspirin, clopidogrel), or NSAIDs.
- INR monitoring is advisable when omega-3 supplements are added to warfarin therapy; most evidence suggests doses of 3–6 g/day do not significantly alter anticoagulant status, but individual variation exists.
- Extended use at 4 g/day in individuals with established CVD or at high CVD risk is associated with a modestly increased risk of atrial fibrillation (documented in STRENGTH and REDUCE-IT trials).
- High doses (≥900 mg EPA plus 600 mg DHA/day) may reduce immune function.
- Omega-3 may add to the blood-pressure-lowering effect of antihypertensive medications; blood pressure monitoring is advisable when initiating supplementation in patients already on antihypertensive therapy.
- Common side effects include fishy aftertaste, belching, gastrointestinal discomfort, and nausea; these are dose-dependent and usually mild.
- Individuals with fish or shellfish allergies should verify product sourcing; algal EPA/DHA is a fish-free alternative.
- Oxidized (rancid) fish oil may have pro-inflammatory effects; product freshness and storage conditions matter.
When to take it
Best taken: with food
What we make of it
The definitive independent trial, 535 people, found no difference from placebo.
The detail
The DREAM study is the large, government-funded trial in this area. In 535 people it found no significant difference between omega-3 and placebo.